Ebola and Marburg viruses: Pathogenesis and development of countermeasures

被引:38
作者
Hensley, LE
Jones, SM
Feldmann, H
Jahrling, PB
Geisbert, TW
机构
[1] USA, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA
[2] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada
[4] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3T 2N2, Canada
[5] NIAID, Integrated Res Facil, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.2174/156652405774962344
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
引用
收藏
页码:761 / 772
页数:12
相关论文
共 122 条
[1]   C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans [J].
Alvarez, CP ;
Lasala, F ;
Carrillo, J ;
Muñiz, O ;
Corbí, AL ;
Delgado, R .
JOURNAL OF VIROLOGY, 2002, 76 (13) :6841-6844
[2]  
[Anonymous], EBOLA VIRUS HAEMORRH
[3]  
[Anonymous], 1978, EBOLA VIRUS HAEMORRH
[4]   Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges-Courbot, MC ;
Capron, M ;
Lansoud-Soukate, J ;
Debré, P ;
Fisher-Hoch, SP ;
McCormick, JB ;
McCormick, JB ;
Georges, AJ .
NATURE MEDICINE, 1999, 5 (04) :423-426
[5]   Inflammatory responses in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges, AJ ;
Georges-Courbot, MC ;
Capron, M ;
Bedjabaga, I ;
Lansoud-Soukate, J ;
Mavoungou, E .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 128 (01) :163-168
[6]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[7]  
Basler CF, 2004, EBOLA AND MARBURG VIRUSES: MOLECULAR AND CELLULAR BIOLOGY, P305
[8]   The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3 [J].
Basler, CF ;
Mikulasova, A ;
Martinez-Sobrido, L ;
Paragas, J ;
Mühlberger, E ;
Bray, M ;
Klenk, HD ;
Palese, P ;
García-Sastre, A .
JOURNAL OF VIROLOGY, 2003, 77 (14) :7945-7956
[9]   THE ASIALOGLYCOPROTEIN RECEPTOR IS A POTENTIAL LIVER-SPECIFIC RECEPTOR FOR MARBURG VIRUS [J].
BECKER, S ;
SPIESS, M ;
KLENK, HD .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :393-399
[10]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709